The index event was defined as the initiation of an SGLT2i in the SGLT2i cohort and a GLP-1 RA in the GLP-1 RA cohort
Contact your GP or diabetes specialist nurse if you experience: Persistent vomiting that prevents adequate fluid or food intake, or lasts more than 24 hours Severe abdominal pain , particularly if sharp, constant, or radiating to the back (which could indicate pancreatitis, a rare but serious adverse effect) Signs of dehydration dark urine, dizziness, dry mouth, reduced urination Inability to tolerate any food or fluids for more than a day Unexplained weight loss that seems excessive or rapid (more than 12 kg per week) Blood in vomit or black, tarry stools Symptoms that worsen rather than improve after the first month of treatment Severe right upper quadrant pain , possibly with fever or yellowing of the skin/eyes (which could indicate gallbladder disease) Seek immediate medical attention (call 999 or attend A&E) if you develop: Severe, unrelenting abdominal pain with vomiting Signs of severe dehydration with confusion or inability to stand Symptoms suggestive of bowel obstruction (absolute constipation with severe bloating and pain) If you experience severe, persistent abdominal pain that could be pancreatitis, stop taking Rybelsus immediately and seek urgent medical assessment
PMID: 121 ScorranoL.De MatteisM
TRIUMPH program overview The TRIUMPH clinical development program includes multiple large-scale trials designed to confirm the Phase 2 findings in broader, more diverse populations
